Dowload our free ebook: your guide to CRPS filled with incredible knowledge on the condition

CRPS Treatment: pain in left hand for 3 years

General details and patient's info

Age:20 years old at the time of treatment.
Home Country:USA.
Illness duration:3 years prior to the Neridronate Treatment.
Cause:Hand injury, crushed by a closing door.
Symptoms:Sharp unstoppable pain, day and night; muscle spasms; swelling; intense burning; impossible to hold things and to carry weights.
Clinical evaluation:Complex Regional Pain Syndrome. 
Time of treatment:July 2022.

Why the Patient decided to undergo the CRPS Treatment in Italy

This patient is a young, brave woman, she always carried her life as “normal” as possible, attending school, spending time with friends, etc. It was clear to her mom however, that her daughter was in a terrible pain, and all the therapies she underwent (including spinal cord stimulator and ketamine infusion) did not bring her any relief. Her mom found out about Neridronate while googling, and they took the trip together few months after.

Medical treatment the Patient underwent in Italy

Complex regional pain syndrome (CRPS) is a severely painful and disabling disease for which a multitude of therapeutic interventions have been proposed. In the past two decades, only Bisphosphonates gained credibility. In recent years, more convincing evidence has become available on the use of Parenteral Neridronate. Since 2014, this drug is registered and marketed in Italy for the treatment of CRPS. To date, the only therapeutic schedule that is recognized to be able to confer benefit is the intravenous (IV) administration of 100 mg given 4 times.

4 neridronate infusions (100mg, I.v. in saline Solution 0,9% 250 ml)

See the Official Study on the Oxford Academics website:
10 days Light Therapy (in hotel room, 30+ more minutes each day)
30 minutes or more of usage of the MTI Light Therapy reduces inflammation, increase micro-circulation, relax nerves and muscles, reduces pain transmission, accelerates healing, regenerates cells, and promotes cells activation.

Daily Report

DAY 1: Arrival at the Venice airport, greeted by her Patient Manager, followed by check-in at her Hotel in Vicenza. Briefing focused on the next days.

DAY 2: Rest day in the hotel, in contact with her Patient Manager, short walk in Vicenza center.

DAY 3: Morning pick-up by her Patient Manager, 1st visit with the Rheumatologist Professor and 1st Neridronate infusion. The patient is in a good mood.

DAY 4: Morning pick-up by her Patient Manager, 2nd Neridronate infusion. The patient feels just a bit tired, but she is curious, so she visits Verona with her Patient Manager.

DAY 5: Morning pick-up by her Patient Manager, 3rd Neridronate infusion.

DAY 6: Morning pick-up by her Patient Manager, 2nd visit with Rheumatologist Professor, 4th Neridronate Infusion. The patient has a light headache, the Rheumatologist Professor prescribes some Tylenol.

DAY 7: Day trip to Venice with the Patient Manager. The patient feels well and appreciates the way everybody has been treating her.

DAY 8: Rest day in contact with her Patient Manager.

DAY 9: Early pick-up from her Patient Manager and drop off Venice airport to fly back home.

Follow up

OCTOBER 2022: (3 months after Neridronate treatment) the patient says that her pain levels are decreasing. Both her and her mother are very optimistic.

NOVEMBER 2022 : (4 months after Neridronate) the pain keeps on lowering down. The patient feels that it is easier to focus on her school activities and duties.

JANUARY 2023: (6 months after Neridronate treatment). The patient refers that she only is in pain from time to time but usually has very good days.

APRIL 2023 :(9 months after Neridronate treatment) The patient says that she is in remission. She is back to all her activities.

JULY 2023 :(12 months Neridronate treatment) The patient feels very good and confirms to be in full remission.


This patient had the best-case scenario in terms of results: after 3 years of fighting CRPS, she reached remission thanks to the Neridronate treatment. Younger patients seem to always respond incredibly well to the treatment, which is another input showing the treatment should be done as soon as possible, in any case.

This is not a medical case study; it merely describes each patient’s journey, and it omits all personal data. The people who redacted it are not doctors but all the facts reported are objective and represent the patient’s reality thanks to the information in our possession. The report is not part of any clinical trials. It was written to provide more information to patients who have made multiple requests for treatment outcomes of cases like theirs.